Core Viewpoint - The company is experiencing growth in the health supplement market, driven by increasing health awareness and consumer demand for preventive healthcare products, leading to a strategic focus on product innovation and market expansion [3][5][19]. Company Overview - The company operates in the pharmaceutical manufacturing industry, specifically in the OTC (over-the-counter) drug and health supplement sectors, with its main product being the 21 Jinweita Multivitamin [3][4]. - The health supplement market in China is expanding, with significant growth potential compared to developed countries, as consumer awareness and demand for dietary supplements increase [4][7]. Industry Trends - The non-prescription drug market is benefiting from a shift towards preventive healthcare, supported by national policies promoting health awareness and consumer education [5][6]. - The aging population in China is driving demand for health management products, with a notable increase in the elderly demographic, which is expected to further boost the health supplement market [8][9]. Business Performance - The company reported a revenue of 641 million yuan, a year-on-year increase of 10.23%, and a net profit of 91.83 million yuan, up 7.24% from the previous year [19]. - The company is focusing on expanding its product matrix in the health supplement sector, enhancing its brand presence, and optimizing its sales channels to improve market competitiveness [10][14]. Product and Brand Strategy - The company has a diverse product range, primarily focusing on vitamins and minerals, and is committed to continuous research and development to meet varying consumer needs [11][12]. - The brand "21 Jinweita" has established itself as a leading name in the vitamin and mineral sector, with recognition in various industry awards and rankings [13]. Marketing and Sales Network - The company has developed a comprehensive marketing network, utilizing both online and offline channels to reach consumers effectively, including major e-commerce platforms [14]. - The company is adapting its sales strategies to align with changing consumer behaviors and preferences, ensuring broad market coverage [14]. Management and Innovation - The company boasts a professional management team with extensive experience in the health product sector, focusing on innovation and compliance with industry standards [15]. - The company has established a robust core technology system for product formulation and quality control, continuously improving its capabilities [16].

Group 1 - Shenjian Co., Ltd. reported a net profit of 33.65 million yuan for 2024, a year-on-year increase of 32.29%, with a proposed cash dividend of 0.5 yuan per 10 shares [1] - Jingce Electronics experienced a net loss of 97.60 million yuan in 2024, transitioning from profit to loss, despite a revenue increase of 5.59% to 2.565 billion yuan [1] - Jingwei Co., Ltd. reported a net profit of 35.54 million yuan for 2024, a decrease of 36.76%, with a proposed cash dividend of 1.00 yuan per 10 shares [1][2] Group 2 - Minsheng Health achieved a net profit of 91.83 million yuan in 2024, a year-on-year increase of 7.24%, with a proposed cash dividend of 1.00 yuan per 10 shares [2] - Zhongshe Co., Ltd. reported a net profit of 10.16 million yuan for 2024, a decline of 76.24%, with a proposed cash dividend of 0.2 yuan per 10 shares [3] - Keyuan Smart reported a net profit of 252 million yuan for 2024, a year-on-year increase of 56.64%, with a proposed cash dividend of 0.4 yuan per 10 shares [4] Group 3 - Beilu Pharmaceutical reported a net profit of 14.54 million yuan for Q1 2025, a year-on-year increase of 26.13%, with revenue of 283 million yuan [5] - Wangsu Technology achieved a net profit of 192 million yuan for Q1 2025, a year-on-year increase of 38.54%, with revenue of 1.235 billion yuan [6] - Keyuan Pharmaceutical reported a net profit of 23.08 million yuan for Q1 2025, a year-on-year increase of 7.25%, despite a revenue decline of 23.98% [7] Group 4 - Guangting Information reported a net profit of 24.03 million yuan for Q1 2025, turning from loss to profit, with revenue of 134 million yuan [9] - Zhaori Technology reported a net loss of 1.23 million yuan for Q1 2025, with revenue of 35.23 million yuan [11] - Huakai Yibai reported a net loss of 15.09 million yuan for Q1 2025, despite revenue growth of 35.08% to 2.292 billion yuan [13] Group 5 - Xinhongye reported a net profit of 34.43 million yuan for Q1 2025, a year-on-year increase of 20.43%, with revenue of 755 million yuan [15] - Huning Co., Ltd. reported a net profit of 3.61 million yuan for Q1 2025, a year-on-year decrease of 45.68%, with revenue of 64.51 million yuan [16] - Camel Co., Ltd. reported a net profit of 237 million yuan for Q1 2025, a year-on-year increase of 51.89%, with revenue of 4.136 billion yuan [17] Group 6 - Hengtong Co., Ltd. reported a net profit of 42.55 million yuan for Q1 2025, a year-on-year increase of 51.62%, with revenue of 313 million yuan [19] - Changqing Technology reported a net profit of 35.38 million yuan for Q1 2025, a year-on-year decrease of 23.80%, with revenue of 246 million yuan [21] - Libaba Co., Ltd. reported a net profit of 34.72 million yuan for Q1 2025, a year-on-year increase of 9.91%, with revenue of 419 million yuan [22] Group 7 - Shouxiangu reported a net profit of 58.37 million yuan for Q1 2025, a year-on-year decrease of 24.32%, with revenue of 171 million yuan [24] - Bojun Technology announced a stock issuance application accepted by the Shenzhen Stock Exchange [24] - Dayou Energy announced the full resumption of production at its Gengcun coal mine, with an annual production capacity of 3.6 million tons [25] Group 8 - Deyang Co., Ltd. successfully acquired land use rights for industrial land in Ningbo for 45.80 million yuan [27] - Tianyu Pharmaceutical's subsidiary received a drug registration certificate for an injectable product [29] - Xingwang Yuda signed a strategic cooperation agreement with the Jilin Province Bionic Robot Innovation Center [30] Group 9 - Lifang Pharmaceutical received approval for clinical trials of a new drug [32] - Zai Sheng Technology reported a net profit of 33.56 million yuan for Q1 2025, a year-on-year increase of 3.69%, with revenue of 324 million yuan [34] - Jinxin Technology reported a net profit of 319,920 yuan for Q1 2025, turning from loss to profit, with revenue of 563 million yuan [36] Group 10 - Huayin Electric reported a net profit of 75.67 million yuan for Q1 2025, a year-on-year increase of 894.61%, with revenue of 2.307 billion yuan [37] - Xinghua Co., Ltd. reported a net loss of 95.51 million yuan for Q1 2025, with revenue of 840 million yuan [38] - Heren Technology reported a net loss of 384,410 yuan for Q1 2025, with revenue of 78.40 million yuan [40] Group 11 - Fenda Technology reported a net profit of 40.45 million yuan for Q1 2025, a year-on-year increase of 84.07%, with revenue of 760 million yuan [41] - Tongda Co., Ltd. reported a net profit of 25.49 million yuan for 2024, a year-on-year decrease of 69.15%, with revenue of 6.201 billion yuan [43] - Zhonghe Holdings reported a net profit of 283 million yuan for 2024, a year-on-year decrease of 54.69%, with a proposed cash dividend of 0.3 yuan per 10 shares [44] Group 12 - Jiantou Energy reported a net profit of 531 million yuan for 2024, a year-on-year increase of 181.59%, with a proposed cash dividend of 1.3 yuan per 10 shares [44] - Guanghua Technology reported a net loss of 205 million yuan for 2024, with revenue of 2.589 billion yuan [45] - Huajin Technology reported a net profit of 29.26 billion yuan for 2024, a year-on-year increase of 8.1%, with a proposed cash dividend of 9 yuan per 10 shares [46] Group 13 - Yingke Medical reported a net profit of 1.465 billion yuan for 2024, a year-on-year increase of 282.63%, with a proposed cash dividend of 1.00 yuan per 10 shares [46] - Solar Energy reported a net profit of 1.225 billion yuan for 2024, a year-on-year decrease of 22.38%, with a proposed cash dividend of 0.56 yuan per 10 shares [46] - Dongfang Electric reported a net profit of 318 million yuan for 2024, a year-on-year decrease of 50.62%, with a proposed cash dividend of 0.32 yuan per 10 shares [47] Group 14 - Tianneng Heavy Industry reported a net loss of 262 million yuan for 2024, with revenue of 3.273 billion yuan [48] - Gangyan High-tech reported a net profit of 249 million yuan for 2024, a year-on-year decrease of 22.08%, with a proposed cash dividend of 1.00 yuan per 10 shares [48] - Shihua Machinery reported a net profit of 96.88 million yuan for 2024, a year-on-year increase of 5.35%, with revenue of 8.037 billion yuan [49] Group 15 - Gongtong Pharmaceutical reported a net loss of 27.59 million yuan for 2024, with revenue of 537 million yuan [51] - Zhongjing Electronics reported a net loss of 87.43 million yuan for 2024, with revenue of 2.932 billion yuan [53] - Yudai Development reported a net loss of 114 million yuan for 2024, with revenue of 388 million yuan [55] Group 16 - Zhenhua Technology reported a net profit of 970 million yuan for 2024, a year-on-year decrease of 63.83%, with a proposed cash dividend of 1.8 yuan per 10 shares [56] - Jierong Technology reported a net loss of 298 million yuan for 2024, with revenue of 1.357 billion yuan [58] - Changgao Electric New reported a net profit of 252 million yuan for 2024, a year-on-year increase of 45.66%, with a proposed cash dividend of 0.8 yuan per 10 shares [60] Group 17 - Shibao Detection announced a plan to acquire 81% of Zhonghuan Lianshu for 52.65 million yuan [61] - Jiangsu Boyun announced a plan to reduce its shareholding by up to 3% [62] - Jingfeng Mingyuan announced a plan to acquire 100% of Yichong Technology for 3.283 billion yuan [63]

杭州民生健康药业股份有限公司 2024 年度内部控制评价报告 杭州民生健康药业股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求(以下简 称企业内部控制规范体系)，结合对杭州民生健康药业股份有限公司(以下简称公司或本公司) 内部控制制度和评价办法，在内部控制日常监督和专项监督的基础上，我们对公司2024年12 月31日(内部控制评价报告基准日)的内部控制有效性进行了评价。 一．重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并 如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行 监督。经理层负责组织领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、 高级管理人员保证本报告内容不存在任何虚假记载、误导性陈述或重大遗漏，并对报告内容 的真实性、准确性和完整性承担个别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真 实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅 能为实现上述目标提供合理保证。此外，由于情况的变化可能导致 ...

证券代码：301507 证券简称：民生健康 公告编号：2025-019 杭州民生健康药业股份有限公司 关于公司及子公司使用自有资金进行现金管理 的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 在不影响日常经营资金需求并有效保障资金安全的前提下，公司及合并报表 范围内的下属子公司使用闲置自有资金适度开展现金管理，有利于提高公司资金 利用率，增加公司收益，最大化利用闲置资金。 杭州民生健康药业股份有限公司（以下简称"公司"）于2025年4月23日召 开第二届董事会第八次会议及第二届监事会第五次会议，分别审议通过了《关于 公司及子公司使用自有资金进行现金管理的议案》，同意公司及合并报表范围内 的下属子公司在最高额不超过人民币6.5亿元的额度内进行现金管理，有效期自 股东大会审议通过之日起12个月。在上述额度及有效期内，资金可循环滚动使用， 期限内任一时点的金额不应超过前述授权额度。该议案尚需提交股东大会审议。 现将具体情况公告如下： 一、现金管理概况 （二）现金管理额度及期限 （一）现金管理目的 公司及合并报表范围内的下属子公司拟在最高额不超过人民币 ...

证券代码：301507 证券简称：民生健康 公告编号：2024-017 杭州民生健康药业股份有限公司 2024 年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何虚 假记载、误导性陈述或者重大遗漏。 根据中国证券监督管理委员会发布的《上市公司监管指引第 2 号——上市公司 募集资金管理和使用的监管要求》和深圳证券交易所发布的《深圳证券交易所上市 公司自律监管指引第 2 号——创业板上市公司规范运作》等有关规定及相关格式指 引的要求，杭州民生健康药业股份有限公司（以下简称"公司"）就 2024 年度募集 资金存放与使用情况专项说明如下： 一、募集资金基本情况 (一) 实际募集资金金额、资金到账时间 二、募集资金管理情况 (一) 募集资金的管理情况 为规范募集资金的存放、管理和使用，提高募集资金使用效率和效益，保护投 资者利益，根据《上市公司监管指引第2号——上市公司募集资金管理和使用的监 管要求》《深圳证券交易所创业板股票上市规则》及《深圳证券交易所上市公司自 律监管指引第2号——创业板上市公司规范运作》等有关法律、法规和规范性文件 及公司《募集资金管理办法 ...

证券代码：301507 证券简称：民生健康 公告编号：2025-020 二、募集资金投资项目情况 根据 杭州民生健康药业股份有限公司首次公开发行股票并在创业板上市招 股说明书》，公司首次公开发行股票募集资金扣除发行费用后，将投资于以下项 目： 杭州民生健康药业股份有限公司 关于使用部分闲置募集资金（含超募资金）进 行现金管理的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 杭州民生健康药业股份有限公司（（以下简称（ 公司"）于 2025 年 4 月 23 日 召开第二届董事会第八次会议及第二届监事会第五次会议，分别审议通过了（ 关 于使用部分闲置募集资金（（含超募资金）进行现金管理的议案》，同意公司在不 影响募集资金投资项目建设和公司正常经营、不改变募集资金使用用途的前提下， 使用最高不超过人民币 7.1 亿元的暂时闲置募集资金（（含超募资金）进行现金管 理，单笔投资产品期限最长不超过 12 个月，有效期自公司股东大会审议通过之 日起 12 个月，公司可在上述额度及期限内滚动使用投资额度。该议案尚需提交 股东大会审议。现将具体情况公告如下： 一、募 ...

杭州民生健康药业股份有限公司 审计委员会对会计师事务所 2024 年度履职情况评估报告和 履行监督职责情况报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理 准则》《国有企业、上市公司选聘会计师事务所管理办法》《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》和《公司章程》《董 事会审计委员会议事规则》等规定和要求，杭州民生健康药业股份有限公司（以 下简称"公司"）董事会审计委员会本着勤勉尽责的原则，恪尽职守，认真履职。 现将董事会审计委员会对会计师事务所 2024 年度履职评估及履行监督职责的情 况汇报如下： 一、2024 年度会计师事务所基本情况 1、基本信息 中汇会计师事务所，于 2013 年 12 月转制为特殊普通合伙，管理总部设立于 杭州，系原具有证券、期货业务审计资格的会计师事务所之一，长期从事证券服 务业务。 企业名称：中汇会计师事务所（特殊普通合伙） 成立日期：2013 年 12 月 19 日 首席合伙人：高峰 截至上年度末（2024 年 12 月 31 日），中汇会计师事务所合伙人数量 116 人，注册会计师人数 694 人，其中签署过证券服务 ...

中汇会计师事务所《（特殊普通合伙）（以下简称《"中汇会计师事务所"）具 有证券、期货相关业务执业资格以及丰富的审计工作经验与能力。在担任公司 2024 年度审计机构期间，中汇会计师事务所遵循《中国注册会计师独立审计准 则》等相关法律、法规和政策的要求，勤勉尽责、细致严谨，并坚持独立、客观、 公正的审计准则，按时完成年度财务审计业务，为公司出具了标准无保留意见的 审计报告，客观、公正地反映了公司的财务状况和经营成果。 证券代码：301507 证券简称：民生健康 公告编号：2025-015 杭州民生健康药业股份有限公司 关于续聘 2025 年度会计师事务所的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 杭州民生健康药业股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开第二届董事会第八次会议，审议通过了《关于续聘公司 2025 年度审计机 构的议案》，同意续聘中汇会计师事务所（特殊普通合伙）为公司 2025 年度财 务审计机构及内部控制审计机构，聘期一年，并提请股东大会授权公司经营管理 层合理确定审计费用并签署相关文件。本议案尚需提 ...

证券代码：301507 证券简称：民生健康 公告编号：2025-022 一、制度修订、废止的具体情况 | 序号 | 制度名称 | 类型 | 是否提交股 | | --- | --- | --- | --- | | | | | 东大会审议 | | 1 | 《股东大会议事规则》 | 修订 | 是 | | 2 | 《董事会议事规则》 | 修订 | 是 | | 3 | 《监事会议事规则》 | 废止 | 是 | | 4 | 《独立董事工作细则》 | 修订 | 是 | | 5 | 《对外担保管理制度》 | 修订 | 是 | | 6 | 《对外投资管理制度》 | 修订 | 是 | | 7 | 《募集资金管理办法》 | 修订 | 是 | | --- | --- | --- | --- | | 8 | 《关联交易管理办法》 | 修订 | 是 | | 9 | 《防止大股东及关联方占用公司资金管理制度》 | 修订 | 是 | | 10 | 《董事、监事、高级管理人员薪酬管理制度》 | 修订 | 是 | | 11 | 《授权管理制度》 | 修订 | 是 | | 12 | 《董事会审计委员会议事规则》 | 修订 | 否 | | 13 | ...

本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 杭州民生健康药业股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日 召开第二届董事会第八次会议，审议通过了《关于公司及子公司向金融机构申请 综合授信额度的议案》，同意公司及合并报表范围内的下属子公司向金融机构申 请总额不超过 2.7 亿元的综合授信额度。现将具体情况公告如下： 证券代码：301507 证券简称：民生健康 公告编号：2025-018 杭州民生健康药业股份有限公司 关于公司及子公司向金融机构申请综合授信额 度的公告 2、根据《公司授权管理制度》，上述申请综合授信额度事项属于董事会审 批权限，无需提交股东大会审议。 四、备查文件 一、本次向金融机构申请综合授信额度的基本情况 根据公司业务发展需要，为提高公司资金利用效率，公司及合并报表范围内 的下属子公司拟向金融机构申请总额不超过 2.7 亿元的综合授信额度，有效期自 董事会审议通过之日起至 2025 年年度董事会召开之日止，具体形式包括但不限 于银行承兑汇票、信用证、票据贴现，开立保函等。在上述额度及期限内，资金 可循环滚动使用， ...